'Landmark' Findings Led to Alecensa Approval for ALK-Positive NSCLC

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

Related Keywords

Upal Basu Roy ,Drug Administration ,Lungevity Foundation ,New England Journal ,Nsclc ,Lung Cancer Treatment ,Alecensa ,Non Small Cell Lung Cancer ,